Compounds such as CLN-081 and sunvosertinib/poziotinib have shown promising therapeutic effects in clinical trials and are being further validated (17), cetuximab and osimertinib or afatinib has demonstrated therapeutic efficacy in patients harboring EGFR ex20ins.Our study summarizes the current literature, conference reports, and clinical trial data on the epidemiology, clinicopathological features, and detection strategies of patients with EGFR ex20ins mutations NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.